Polycystic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly, in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. The launch of Otsuka’s Jynarque / Jinarc / Samsca (tolvaptan) introduced the first disease-specific therapy for ADPKD. Several more therapies for ADPKD are in clinical trials, including Reata Pharmaceutical’s bardoxolone methyl, Galapagos’s GLPG2737, Kadmon’s tesevatinib, and Xortx Therapeutics’ oxypurinol. Some of these therapies are expected to fulfill current unmet needs in the treatment of ADPKD.

Questions answered

  • What do key opinion leaders think about the emerging therapies bardoxolone methyl, GLPG2737, tesevatinib, and oxypurinol? How will emerging therapies differentiate themselves in an increasingly crowded market?
  • How will the anticipated genericization of Otsuka’s Jynarque / Jinarc / Samsca affect the uptake of branded and emerging therapies?
  • What effect have the discontinuations of Sanofi / Genzyme’s venglustat, Regulus Therapeutics’ RGLS-4326, and Palladio Bioscience’s lixivaptan had on the ADPKD therapy market?
  • What are the key unmet needs in ADPKD, and which therapies likely to fulfill them?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement:

Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents